Managing ADHD medication side effects — practical guide

What no one explains enough

When your psychiatrist prescribes an ADHD treatment, the consultation lasts 20-40 minutes. Side effects are listed — but quickly. Then you go home, read the leaflet, see 17 possible effects, and panic.

This page exists to give you a proportionate view. Which effects are common but manageable. Which effects require consulting. How to handle it, concretely, week by week.

Understand before you apply

What causes side effects?

ADHD treatments act on dopaminergic and noradrenergic neurotransmission. These systems aren’t contained in the brain — dopamine and noradrenaline also regulate:

• The heart and vessels (heart rate, blood pressure).
• Appetite (known anorexigenic effect).
• Sleep (activation, vigilance).
• Mood and anxiety.
• The digestive system (motility, dry mouth).

Side effects are often the other face of the therapeutic mechanism — not a bug, a feature.

The golden rule

Common effects — and what to do

1. Reduced appetite

Frequency: 30-40% of stimulant users across studies ^[11] . Often more marked with amphetamines than with methylphenidate.

Evolution: often peaks in the first 2-4 weeks, then fades for many. Can persist at variable degrees.

Practical strategies:

2. Sleep-onset insomnia

Frequency: 10-30% of patients, very dependent on timing and formulation.

Causes: residual activation of the noradrenergic system in the evening.

Strategies:

3. Nervousness, anxiety, irritability

Frequency: very variable. Often more marked with amphetamines than methylphenidate.

Evolution: if it happens, often in the first 1-3 weeks, then diminishes.

Strategies:

4. Headaches, dizziness

Frequency: very common at start (up to 25%).

Evolution: often fade after 1-2 weeks.

Strategies:

5. Dry mouth, constipation

Strategies:

6. Cardiovascular effects — regular monitoring

Average measurements under stimulants ^{[9] [10]} :

• Heart rate: +5 to 10 beats per minute.
• Systolic blood pressure: +2 to 4 mmHg.

Modest effect for most. Becomes concerning when stacked with other factors (pre-existing hypertension, heavy smoking, cardiac comorbidity).

Recommended follow-up ^[7] :

• Heart rate and blood pressure at each follow-up consultation (every 3-6 months).
• Weight, BMI every 3-6 months.
• Cardiological evaluation if new symptoms (chest pain, palpitations, syncope).

The long-term debate — honestly

What Zhang 2024 (JAMA Psychiatry) says

The Swedish study on 278,027 ADHD people followed up to 14 years ^[1] :

+23%

CVD risk after 5+ years of ADHD treatment (vs non-users)

What increases (significantly):

• Hypertension (OR 1.72 after 3-5 years)
• Arterial disease

What does NOT significantly increase:

• Arrhythmias
• Myocardial infarction
• Stroke

Important nuances:

• Risk that rises in the first 3 years then stabilises.
• Effect more marked for stimulants than non-stimulants.
• No clear linear dose-response relationship beyond 5 years.
• This is relative risk — in absolute terms, the increase remains modest for most patients without other risk factors.

The counterpoint: Li 2024 (JAMA) on mortality

-21%

all-cause mortality in ADHD people starting treatment

Li et al.’s study ^[2] on 148,578 Swedish people with ADHD shows that starting treatment is associated with lower all-cause mortality, especially from non-natural causes (suicides, accidents, overdoses).

Reasonable interpretation:

• Untreated ADHD has its own morbidity/mortality (suicides, road accidents, risky behaviours, unmanaged comorbidities).
• Treatment reduces these risks.
• But it introduces a modest chronic cardiovascular cost.
• The benefit/risk balance remains positive for most patients, but must be individualised.

On off-label doses

Farhat 2024 ^[4] shows clearly: off-label doses provide no additional clinically relevant benefit, and increase dropouts for adverse effects. Staying within the authorised range = reasonable principle.

Cardiovascular workup before starting

What guidelines recommend

NICE NG87 ^[7] and HAS ^[8] :

Situations requiring a cardiology consultation

Consultation signals — a clear map

Level 1 — Emergency consultation (emergency services)

Level 2 — Contact prescriber within 24-48 hours

Level 3 — To mention at follow-up consultation

• Persistent but manageable appetite suppression
• Dry mouth, mild constipation
• Headaches early in treatment that improve
• Insomnia managed by timing adjustment
• Slight end-of-dose rebound

Questions rarely asked

”Should I stop if I get pregnant?”

Individual medical decision ^[5] . Most recommendations favour stopping during pregnancy unless untreated ADHD poses more risk than treatment. Don’t stop abruptly without advice. Dedicated consultation with psychiatrist + obstetrician.

”And for breastfeeding?”

Methylphenidate and atomoxetine pass into breast milk. Individual decision with paediatric and psychiatric advice. No uniform rule — but not an absolute contraindication.

”Can I do intensive sport on treatment?”

Generally yes, with precautions: increased hydration, caution with heat (stimulants alter thermal regulation), monitoring heart rate on exertion. Competitive sport → cardiology opinion for fitness.

”Can I stop treatment whenever I want?"

"Do side effects disappear with continued use?”

Yes, often, for: headaches, nausea, initial adaptation, startup irritability. No, often, for: reduced appetite (attenuated but persistent), modest cardiovascular effects (stable over time). Long-term data (> 5 years) remain more limited ^[3] .

The follow-up framework — what to expect

Recommended standard follow-up ^{[7] [8]} :

The first three weeks were rough: no hunger, insomnia, headaches. I nearly stopped. My psychiatrist told me to hold on 2 more weeks. By week 5 everything stabilised. It isn’t magic, but I function infinitely better. The key: don’t stop without talking about it.

Takeaways

Go further

• Methylphenidate — full detail
• Lisdexamfetamine (Elvanse / XURTA)
• Atomoxetine (Strattera) — non-stimulant
• ADHD medication shortages in France — practical guide
• The adult ADHD diagnostic pathway
• In a crisis: In France 3114 (free 24/7). UK: Samaritans 116 123. US: 988.
• Medical emergency: 112 (EU), 999 (UK), 911 (US/CA), 000 (AU), 15 (FR).